Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Emi Takashita; Chiharu Kawakami; Rie Ogawa; Hiroko Morita; Seiichiro Fujisaki; Masayuki Shirakura; Hideka Miura; Kazuya Nakamura; Noriko Kishida; Tomoko Kuwahara; Akira Ota; Hayato Togashi; Ayako Saito; Keiko Mitamura; Takashi Abe; Masataka Ichikawa; Masahiko Yamazaki; Shinji Watanabe; Takato Odagiri

doi:10.2807/1560-7917.ES.2019.24.12.1900170

Rapid communication Open Access

Like 0

Download

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
Emi Takashita¹ , Chiharu Kawakami² , Rie Ogawa¹ , Hiroko Morita¹ , Seiichiro Fujisaki¹ , Masayuki Shirakura¹ , Hideka Miura¹ , Kazuya Nakamura¹ , Noriko Kishida¹ , Tomoko Kuwahara¹ , Akira Ota³ , Hayato Togashi³ , Ayako Saito⁴ , Keiko Mitamura⁵ , Takashi Abe⁶ , Masataka Ichikawa⁷ , Masahiko Yamazaki⁸ , Shinji Watanabe¹ , Takato Odagiri¹
View Affiliations Hide Affiliations

Affiliations: ¹ Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan ² Yokohama City Institute of Public Health, Kanagawa, Japan ³ Saiseikai Yokohamashi Nanbu Hospital, Kanagawa, Japan ⁴ Saito Children’s Clinic, Kanagawa, Japan ⁵ Eiju General Hospital, Tokyo, Japan ⁶ Abe Children’s Clinic, Kanagawa, Japan ⁷ Ichikawa Children’s Clinic, Kanagawa, Japan ⁸ Zama Children’s Clinic, Kanagawa, Japan

Correspondence:
Takato Odagiri
todagiri nih.go.jp
View Citation Hide Citation

Citation style for this article: Takashita Emi, Kawakami Chiharu, Ogawa Rie, Morita Hiroko, Fujisaki Seiichiro, Shirakura Masayuki, Miura Hideka, Nakamura Kazuya, Kishida Noriko, Kuwahara Tomoko, Ota Akira, Togashi Hayato, Saito Ayako, Mitamura Keiko, Abe Takashi, Ichikawa Masataka, Yamazaki Masahiko, Watanabe Shinji, Odagiri Takato. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill. 2019;24(12):pii=1900170. https://doi.org/10.2807/1560-7917.ES.2019.24.12.1900170 Received: 06 Mar 2019; Accepted: 21 Mar 2019

Abstract

In January 2019, two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA), which confers reduced susceptibility to baloxavir, were detected from epidemiologically unrelated hospitalised children in Japan. The viruses exhibited reduced susceptibility to baloxavir but were susceptible to neuraminidase inhibitors. Only one of the two children had been treated with baloxavir. An epidemiological analysis suggests possible transmission of the PA I38T mutant A(H3N2) virus among humans.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.12.1900170

2019-03-21

2021-05-07

Click here for cited by

http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.12.1900170

From This Site

/content/10.2807/1560-7917.ES.2019.24.12.1900170

dcterms_title,dcterms_subject,pub_keyword

-contentType:Journal -contentType:Contributor -contentType:Concept -contentType:Institution

10

5
PubMed
Google Scholar

Full text loading...

/deliver/fulltext/eurosurveillance/24/12/eurosurv-24-12-3.html?itemId=/content/10.2807/1560-7917.ES.2019.24.12.1900170&mimeType=html&fmt=ahah

References

Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al. , On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698 PMID: 30670142
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. https://doi.org/10.1038/s41598-018-27890-4 PMID: 29941893
Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2018;9(3026):3026. https://doi.org/10.3389/fmicb.2018.03026 PMID: 30574137
Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800666 PMID: 30670144
World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. PMID: 23061103
Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, et al. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Influenza and Other Infections; 2019 February 19-20; Tokyo, Japan.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. , Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913-23. https://doi.org/10.1056/NEJMoa1716197 PMID: 30184455
Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res. 2019;164:91-6. https://doi.org/10.1016/j.antiviral.2019.02.007 PMID: 30771405
National Institute of Infectious Diseases (NIID). Antiviral resistance surveillance in Japan. Tokyo: NIID. Available from: http://www.nih.go.jp/niid/en/influ-resist-e.html

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Citation style for this article: <a href="/search?value1=Emi+Takashita&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Takashita Emi</a>, <a href="/search?value1=Chiharu+Kawakami&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kawakami Chiharu</a>, <a href="/search?value1=Rie+Ogawa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ogawa Rie</a>, <a href="/search?value1=Hiroko+Morita&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Morita Hiroko</a>, <a href="/search?value1=Seiichiro+Fujisaki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fujisaki Seiichiro</a>, <a href="/search?value1=Masayuki+Shirakura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Shirakura Masayuki</a>, <a href="/search?value1=Hideka+Miura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Miura Hideka</a>, <a href="/search?value1=Kazuya+Nakamura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nakamura Kazuya</a>, <a href="/search?value1=Noriko+Kishida&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kishida Noriko</a>, <a href="/search?value1=Tomoko+Kuwahara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kuwahara Tomoko</a>, <a href="/search?value1=Akira+Ota&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ota Akira</a>, <a href="/search?value1=Hayato+Togashi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Togashi Hayato</a>, <a href="/search?value1=Ayako+Saito&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Saito Ayako</a>, <a href="/search?value1=Keiko+Mitamura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mitamura Keiko</a>, <a href="/search?value1=Takashi+Abe&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abe Takashi</a>, <a href="/search?value1=Masataka+Ichikawa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ichikawa Masataka</a>, <a href="/search?value1=Masahiko+Yamazaki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yamazaki Masahiko</a>, <a href="/search?value1=Shinji+Watanabe&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Watanabe Shinji</a>, <a href="/search?value1=Takato+Odagiri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Odagiri Takato</a>. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(12):pii=1900170. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.12.1900170" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.12.1900170</a> Received: 06 Mar 2019;   Accepted: 21 Mar 2019

/content/10.2807/1560-7917.ES.2019.24.12.1900170

Data & Media loading...

Submit comment

Comment moderation successfully completed

Submit your article here

Submit an Article

Tools

News/announcements

ESCAIDE 2021 call for abstracts is open from 19 April to 19 May. The conference welcomes abstracts in all areas related to infectious disease prevention and control, including epidemiology, public health microbiology, surveillance, and the application of tools and methods to support infectious disease outbreaks or interventions. There will also be a late breaker call in September for issues arising after the close of the main abstract call. More information and guidelines can be found here.

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Abstract

Click here for cited by

From This Site

PubMed

Google Scholar